Abstract: A process for dispersing pigment in an eyelash coating composition including water, at least one pigment, and at least one wax, by adding at least one C10-C30 alkyl phosphate and at least one C8-C24 fatty alkyl ether of polyethylene glycol, the ether having from 1 to 19 ethylene glycol units and having an HLB<8 at 25° C., during preparation of the eyelash coating composition to disperse the at least one pigment in the eyelash coating composition.

Abstract: A fluoride composition applied to teeth. The fluoride composition comprises microcrystalline wax, mineral oil, vitamin E, amorphous calcium phosphate or ACP, guar gum, and sodium fluoride. The amorphous calcium phosphate and sodium fluoride are released gradually and when dissolved in saliva form ionic fluoride and ionic calcium that aid in re-mineralization of the tooth enamel. Enhanced fluoride treatment is obtained relative to a conventional fluoride rinse. A similar composition may be used as a protective coating material to protect whitened or bleached teeth.

Abstract: The present invention relates to a hair treatment process comprising the application to the hair of an aqueous-alcoholic composition comprising at least 5% of at least one C1-C7 alcohol and at least one organic monoacid, followed by a straightening/relaxing step using a straightening iron at a temperature of at least 100° C. The process of the invention allows good straightening of the hair, while durably reducing the volume and the frizziness effect of the hair.

Abstract: A cosmetic composition for caring for and/or making up the skin and/or the lips, containing, in a physiologically acceptable medium, includes at least: one active agent comprising at least one glycol with a C4-C16 hydrocarbon-based chain and/or a hydroxylated ester resulting from the esterification of polyol and/or of C4-C16 carboxylic acid(s), and one additional agent chosen from essential oils, agents for promoting capillary circulation and temperature regulators, and mixtures thereof.

Abstract: The invention relates to a solid cosmetic antiperspirant composition comprising (a) antiperspirant active, (b) hydroxyalkyl urea, and, (c) a carrier material, selected from: a natural oil that comprises a triglyceride of an unsaturated carboxylic acid; polyalkylene glycol; or a mixture thereof; and a method of production of the antiperspirant composition.

Abstract: The invention relates to a cosmetic composition comprising: (a) at least 2% by weight, relative to the total weight of the composition, of one or more compounds chosen from urea and/or urea derivatives, (b) one or more polymeric thickeners chosen from nonionic, cationic, amphoteric polymeric associative thickeners or anionic polymeric associative thickeners comprising one or more acrylic and/or methacrylic units. The invention also relates to the use of this composition for straightening keratin fibres. Finally, the invention relates to a process for straightening keratin fibres.

Abstract: Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound represented by the formula I wherein the dashed bonds represent the presence or absence of a double bond which can be in the cis or trans configuration and A, B, Z, X, R1 and R2 are as defined in the specification and a penetration enhancer. Such compositions are used in stimulating hair growth of human or non-human animals.

Abstract: The invention relates to a process of manufacture of a solid cosmetic antiperspirant in the form of a stick comprising from 0.0005 to 3 wt. % of a hydroxyalkyl urea, the process comprising the steps of comprising: (a) providing a stick dispenser comprising a stick barrel; (b) providing a first mixture comprising a solvent and gellant and heating the mixture to a temperature above the melting point of the gellant; (c) providing a second mixture comprising a hydroxyalkyl urea and a carrier material selected from the group consisting of: a natural oil that comprises a triglyceride of an unsaturated carboxylic acid, and polyalkylene glycols having a molecular weight of up to 650 Daltons, and heating this mixture to a temperature of 65° C. or above; (d) mixing together of the first and second mixtures; (e) addition of an antiperspirant active to the mixture (d); and, (f) filling a stick barrel with a portion of the mixture (e).

Abstract: Disclosed herein are methods of making personal care compositions comprising animal DNA. The DNA may be extracted from animal tissues or cultured animal cells, or synthesized chemically or enzymatically. The personal care compositions may include shampoos, lotions, cosmetics, and the like. Also disclosed herein are personal care compositions comprising animal DNA prepared according to the methods disclosed herein.

Abstract: An objective of the present invention is to provide a surfactant composition which hardly causes the formation of an insoluble salt and which contains a safe and extremely stable micelle or vesicle. Also, an objective of the present invention is to provide a hair cosmetic material which contains the surfactant composition. The surfactant composition according to the present invention is characterized in comprising a micelle or a vesicle which contain surfactin and a specific cationic surfactant.

Abstract: Hair treatment agents include, with respect to the weight thereof, 0.0001-10 wt % of at least one oligopeptide that has at least one amino acid sequence Glu-Glu-Glu (formula (I)), wherein the amino group can be free or protonated and the carboxyl groups can be free or deprotonated, and 0.0001-10 wt % of at least one ester of hyaluronic acid with lipoic acid, formic acid, or mixtures thereof. With such agents, hyaluronic acid esters and certain oligopeptides intensify each other in the positive effect thereof on the hair and the hair follicles.

Abstract: Hair treatment compositions include—based in each case on the weight thereof—0.0001% to 10% by weight at least one oligopeptide having at least one Glu-Glu-Glu amino acid sequence, wherein the amino group may be free or protonated and the carboxyl groups may be free or deprotonated, and 0.0001% to 10% by weight at least one proteolipid of the formula (I) in which R1 is a straight-chain hydrocarbyl radical having 8 to 22 carbon atoms, R2 is (—CH2)y—CH3, with y=0 to 22, Y is —H or —OH, X? is a physiologically acceptable anion, Hy is an oligopeptide residue from keratin hydrolysate, and x has values from 0 to 22. In these compositions, proteolipids and oligopeptides have mutually enhancing positive effects on the hair and the hair follicle.

Abstract: The present invention relates to the field of dental care, in particular, to a dental care product such as toothpaste (dentifrice), prophylactic paste, tooth powder, tooth polish, tooth gel, chewing gum, candy, lozenge, mouthwash, whitening strip, coated dental floss, coated toothbrush, paint-on gel, varnish, veneer, and tube, syringe or dental tray comprising a gel or paste, mouthwash, whitening strips and trays for whitening teeth, wherein the product comprises mineral particles such as crystals and a compound, preferably, a protein capable of forming a matrix which is a hydrogel, wherein the product comprises a fluorophore. The mineral particles may comprise, e.g., calcium phosphate, preferably, hydroxyapatite, preferably, in crystalline form. The protein matrix may comprise, e.g., a self-assembling peptide. The product also comprises a fluorophore, which may be a fluorescent amino acid residue of the protein matrix.

Abstract: The present invention relates to the use of a polysaccharide selected from the group of non-modified polysaccharides, chemically modified polysaccharides and physically modified polysaccharides, in antiperspirant cosmetic agents, the use of these polysaccharides resulting in an excellent reduction and/or prevention of textile discoloration and/or textile stains.

Abstract: [Object] Provided is a water-based liquid cosmetic which exhibits excellent usability such as density of drawn line and convenience of drawing as well as can discharge a sufficient amount of liquid even when being formed into an automatic pen type, and also can form a cosmetic film exhibiting both lasting properties and washability. [Solving Means] The water-based liquid cosmetic according to the present invention is a water-based liquid cosmetic which includes a film-forming agent, a coloring pigment, and water, in which a sulfonated polyester (A) and a polymer (B) containing an alkyl (meth)acrylate monomer as a constitutional unit are contained at from 2 to 11% by mass and from 2 to 18% by mass with respect to a total amount of the cosmetic, respectively, as the film-forming agent.

Abstract: A cosmetic composition is provided that includes an elastomer and at least one cosmetic component optionally in a cosmetically acceptable medium. The elastomer is according to the general formula: A-B-A or B-A-B, wherein each A independently comprises a polysiloxane moiety having at least two siloxy (Si—O) groups and wherein each B independently comprises a moiety, or a precursor thereof, having at least two carboxyl groups and wherein B is bonded to a silicon atom in A.

Abstract: The present invention concerns a cosmetic antiperspirant composition comprising at least one substance selected from the group consisting of cosmetic oils which are liquid at 20° C. and 1,013 hPa, odorants and waxes, at least one antiperspirant aluminum salt in a total amount of 1 to 80 wt %, based on the total weight of the cosmetic antiperspirant composition, and at least one compound of the formula (S-I), in which X+ is H+, Li+, Na+, K+, NH4+, ½ Mg2+, ½ Ca2+, ½ Mn2+, ½ Zn2+, ? Al3+, ¼ Zr4+ or at least one antiperspirant aluminum salt and R1 is a linear or branched, saturated or unsaturated alkyl group having 1 to 10 carbon atoms, the addition of the at least one compound of the formula (S-I) resulting in effective activation of the at least one antiperspirant aluminum salt, in eminent stabilization of this activated state and in outstanding sweat diminution.

Abstract: The present invention relates to a cosmetic antiperspirant agent including a) at least one substance selected from the group of cosmetic oils which are liquid at 20° C.

Abstract: The present invention relates to a cosmetic antiperspirant composition comprising a) at least one substance selected from the group consisting of cosmetic oils which are liquid at 20° C. and 1013 hPa, odorants and waxes, b) at least one antiperspirant aluminum salt in a total amount of 0.1 to 80 wt %, based on the total weight of the cosmetic antiperspirant composition, and c) at least one compound of formula (LA-I), in which R1 is a linear or branched alkyl group having 1 to 10 carbon atoms, and X+ is Li+, K+, NH4+, ½ Mg2+, ½ Ca2+, ½ Mn2+, ½ Zn2+, ? Al3+, ¼ Zr4+ or at least one antiperspirant aluminum salt, the addition of the at least one compound of formula (LA-I) resulting in effective sealing of the efferent ducts of the sweat gland(s).

Abstract: This application discloses an aqueous dispersion of waxes, polymers, pigments and other functional additives, which can be used as a concentrate of an eye make-up composition. The dispersion contains about 70% solids and can be diluted at room temperature and adjusted with additional ingredients if desired, which enables commercial cosmetic manufacturers to develop and manufacture new formulations with the minimal effort and cost.

Abstract: The present invention relates to an anhydrous liquid dyeing composition comprising one or more oil liquid at 20° C., one or more oxidative dye precursor, at least one anionic and at least one nonionic surfactant for achieving intensive homogeneous colors on hair.

Abstract: The present document describes a personal care formulation comprising from about 2% to about 50% (vol/vol) of at least one edible oil; from about 0.02% to about 0.08% (wt/vol) of at least one edible abrasive; and a thickening agent mixture comprising from about 3% to about 66% (vol/vol) of at least one first thickening agent chosen from aloe vera gel, aloe vera juice, xanthan gum, and cellulose gum, or from about 0.1% to about 0.3% (wt/vol) of carrageenan, or combinations thereof. The present document also describes use of the formulation of skin care and oral hygiene.

Abstract: A method for manufacturing an ingestible film, an apparatus for manufacturing an ingestible film, an ingestible film and a pharmaceutical dosage form comprising the same is provided. The method comprises providing a matrix comprising at least a solvent and a polymer; a film forming step of forming a wet film from the matrix; a heating step of heating said wet film by radiation originating from a radiation source to obtain a heated wet film having a temperature of at least 22° C.; and a drying step of drying the heated wet film using a drying means.

Abstract: The invention provides storage stable sublingual formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering the sublingual formulations of the present invention to a patient in need thereof.

Abstract: The present invention generally relates to topical compositions and methods of using the same. A preferred topical pharmaceutical composition comprises a nitric oxide-releasing active pharmaceutical ingredient in admixture with a hydrophilic composition and a hydrophobic composition wherein the nitric oxide-releasing active pharmaceutical ingredient comprises a nitric oxide-releasing compound having a diazeniumdiolate functional group.

Abstract: The present invention provides pharmaceutical compositions for intranasal delivery of a benzodiazepine. The composition may contain a therapeutically effective amount of a benzodiazepine or a pharmaceutically acceptable salt thereof, and a permeation enhancer. The permeation enhancer may be propylene glycol or a Hsieh permeation enhancer. The present compositions have excellent bioavailability. After administration of the present compositions, therapeutically effective plasma levels of the benzodiazepine may be achieved rapidly. The present pharmaceutical composition may be used to treat a patient suffering from anxiety, epilepsy, insomnia, agitation, seizures, muscular disorders, alcohol dependence, and drug withdrawal.

Abstract: Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol.

Abstract: The present invention concerns the use of Fosfetrol (diethylstilbestrol diphosphate) in a method of curative or palliative treatment of cancer in female mammals, said method comprising orally administering Fosfestrol in a daily dosage of at least 500 mg. Examples of cancers that can be treated by the present method include breast cancer, endometrium cancer and ovarian cancer. The invention further provides an oral dosage unit containing at least 500 mg of Fosfestrol.

Abstract: A cannabis infused chewing composition imparting extracts from cannabis plants to a user for medicinal and recreational purposes. The cannabis infused chewing composition includes a quantity of cannabis plant matter, a quantity of cannabis extract, a quantity of bonding composition, a quantity of moisturizer, and a quantity of flavor enhancer. The quantity of cannabis plant matter, the quantity of cannabis extract, the quantity of moisturizer, and the quantity of flavor enhancer are homogenously amalgamated into a chewable mixture by the quantity of bonding composition. A quantity of shredded tobacco can be included to impart nicotine and other desired tobacco extracts to the user. The shredded tobacco is infused with the quantity of cannabis extracts in a similar manner to the quantity of cannabis plant matter and heterogeneously combined with the chewable mixture.

Abstract: A gastroretentive drug formulation for the sustained release of an active agent in the gastrointestinal tract comprises an internal layer or compartment comprising an active agent and one or more pharmaceutical excipients, of which at least one is a polymer and two membranes forming together an envelope around the inner membrane, each membrane comprising at least one polymeric combination of an enteric polymer which is not soluble in gastric juice, and an hydrophilic swelling polymer, and at least one plasticizer.

Abstract: The present invention relates to amoxicillin trihydrate compositions having a surface area of from 1.0 to 2.5 m2·g?1 that are free of organic contaminants such as dichloromethane, isopropanol, pivalic acid and triethyl amine and that have a purity of from 97.0% to 99.99%. Furthermore, the present invention relates to a method for the preparation of said amoxicillin trihydrate compositions and to the use of said compositions for the treatment of a bacterial infection.

Abstract: Disclosed are dry granules comprising temozolomide and tartaric acid as a pH stabilizer, a pharmaceutical composition including the dry granules with improved stability and a method of preparing the same.

Abstract: The present invention provides pharmaceutical compositions suitable for oral delivery of active agent, such as peptides and small molecules, and methods for treating subjects in need thereof. The pharmaceutical compositions of the present invention enhance the bioavailability of therapeutic active agents.

Abstract: The present invention is directed to oral neuro-attenuating ketamine (NAKET) tablet formulations, and methods of administration, which ensure the steady release of a therapeutically effective concentration of ketamine from an oral tablet without neurologically toxic spikes in ketamine concentration. In particular, the present invention provides single layer oral tablet formulation of NAKET. In a specific embodiment, the NAKET tablet formulation, and methods of administration provide steady administration of NAKET to a subject for 24 hours or greater, for example, up to 36 hours, after a single administration event.

Abstract: The invention relates to a pharmaceutical dosage form, preferably with controlled release of a pharmacologically active compound (A) contained therein, the pharmaceutical dosage form very preferably being tamper-resistant and most preferably having a breaking strength B1 of at least 500 N in direction of extension E1 and having a breaking strength B2 of less than 500 N in direction of extension E2.

Abstract: The invention relates to a tamper-resistant tablet comprising (i) a matrix material in an amount of more than one third of the total weight of the tablet; and (ii) a plurality of particulates in an amount of less than two thirds of the total weight of the tablet; wherein said particulates comprise a pharmacologically active compound and a polyalkylene oxide; and form a discontinuous phase within the matrix material; and method of using said tablet to treat pain and other conditions.

Abstract: A coating agent containing 1% to 7% by mass of hydroxyalkyl cellulose, relative to the total mass of the coating agent, in which the amount of a hydroxyalkyl group, relative to the total mall of the hydroxyalkyl cellulose, is more than 50% to 60% by mass, is obtained. A solid formulation is obtained by spraying the coating agent onto a plane tablet.

Abstract: The present invention provides a magnetic nano core-shell capsule for drug delivery, which including: a plurality of amphiphilic protein, a plurality of iron oxide nanoparticles, a hydrophilic drug and a hydrophobic drug. Wherein the magnetic nano core-shell capsule has good biocompatibility duo to the amphiphilic protein as the material, and it only needs single step emulsion to form its nano hollow structure. Therefore, the magnetic nano core-shell capsule of the present invention has high drug loading capacity, the ability of encapsulating hydrophobic and hydrophilic pharmaceuticals simultaneously and characteristic of controlled-release drug delivery. Thus it can be used for targeted drug delivery, magnetic resonance imaging and hyperthermia.

Abstract: Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric nanoparticle form of thyroid hormone agonist, partial agonist or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Nanoparticle forms of thyroid hormone or thyroid hormone analogs as well as uses thereof are also disclosed.

Abstract: The present invention includes a low dose and sustained release formulation of 2,4-dinitrophenol (DNP). The compositions of the invention are useful for preventing or treating a disease or disorder, such as non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, insulin resistance and/or diabetes, in a subject in need thereof.

Abstract: Some embodiments of the present disclosure include an encapsulated islet for treating diabetes. The encapsulated islet may include a semi-permeable capsular membrane having a plurality of layers including an outer immunoprotection layer, a bridging layer, and an inner backbone layer. A continuous fluid-flow manufacturing process may start production of all membrane layers simultaneously, but at different growth rates for different layers. Each layer may have a plurality of pores, wherein the pores increase in size from the immunoprotection layer to the backbone layer, creating the tapered conduits. The semi-permeable capsular membrane may include the following layers, in order from outermost layer to innermost layer: an immunoprotection layer, a bridging layer, and a backbone layer.

Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) and other CNS stimulant responsive conditions include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 5 to 8 hours or longer, followed by an extended release.

Abstract: A transdermal patch includes a protective layer, a matrix layer, an adhesive layer, and a cover layer. The cover layer is at least partially bi-elastic, and the adhesive layer comprises an acrylic copolymer having hydroxyl functional groups. The matrix layer comprises a physiologically effective amount of buprenorphine or pharmaceutically acceptable salts thereof.

Abstract: A topical drug delivery patch (1) comprising a drug delivery layer (3) including microspheres (2) encapsulating a drug, said microspheres being carried in a hydro gel. The drug delivery layer has a support layer (5) which is attached to a first face of the drug deliver layer and a releasable protective layer (4) attached to a second face of the drug delivery layer. The releasable protective layer can be peeled away do the patch can be applied to the skin to release drugs in the microspheres. The patch is particularly useful for treating skin conditions such as psoriasis and eczema.

Abstract: The present invention is a patch comprising a support, and an adhesive layer disposed on at least one surface of the support and formed of an adhesive composition comprising a drug and an adhesive, wherein the drug is cytisine or a salt thereof, and the adhesive composition has an acid value of 10 or less.

Abstract: The invention relates to an at least three-layer transdermal therapy system (TTS), which contains, in particular, rotigotine as an active ingredient. The TTS comprises an active ingredient-containing central layer, which comprises at least one hygroscopic polymer or copolymer, an inner, active ingredient-permeable layer and an outer layer.

Abstract: Transdermal drug delivery systems and compositions containing estradiol. The systems and compositions can include levulinic acid in an amount to enhance transdermal permeation of estradiol and a pharmaceutically acceptable carrier. The systems and compositions can optionally include a solubilizing agent and additional permeation enhancers. Pharmaceutically acceptable carriers can include adhesives, particularly acrylate copolymers, gels, creams, ointments, solutions, suspensions, and pastes.

Abstract: A use of polygodial or a structural derivative thereof, or a plant extract containing polygodial or a structural derivative thereof for the manufacture of a medicament for treating or preventing a viral infection, or a condition or disease resulting from a viral infection.

Abstract: An oral composition that improves intestinal flora via oral intake includes astaxanthin as an active ingredient, and excludes a component that can form skin tissue, the composition improving the intestinal flora by reducing or suppressing either or both of an increase in gram-negative bacteria and an increase in bacteria that belong to the Clostridium coccoides group.

Abstract: Aqueous compositions suitable for topical administration to the human or animal eye contain at least one water-soluble polymeric ophthalmic lubricant, such as hyaluronate, carbomer gel or hypromellose, together with a water-soluble analgesic. The analgesic may be an opiod, particularly an opioid having an affinity for 5-HT receptors, such as tramadol. The aqueous compositions may for example be used as artificial tears, and as general ophthalmic lubricants for treating conditions such as dry eye or blepharitis. Further compositions combine ophthalmologicallyactive agents, such as pharmaceuticals, with opioids, such as tramadol in particular. These compositions may be used to treat the eye while reducing pain or discomfort that would normally be produced by administering these particular pharmaceuticals to the eye, and increasing the efficacy of the pharmaceuticals.